Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Highlights on pembro + CRT in high-risk locally advanced cervical cancer: The KEYNOTE-A18 study

Dr. Domenica Lorusso reports on key results from ESMO Congress 2023 on LBA38:

Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study#ESMO23, Domenica Lorusso, KEYNOTE-A18, LBA38, advanced cervical cancer, pembrolizumab, chemotherapy

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.